ATE294863T1 - Neuartige vegf-ähnliche faktoren - Google Patents

Neuartige vegf-ähnliche faktoren

Info

Publication number
ATE294863T1
ATE294863T1 AT97930804T AT97930804T ATE294863T1 AT E294863 T1 ATE294863 T1 AT E294863T1 AT 97930804 T AT97930804 T AT 97930804T AT 97930804 T AT97930804 T AT 97930804T AT E294863 T1 ATE294863 T1 AT E294863T1
Authority
AT
Austria
Prior art keywords
vegf
gene
isolated
protein
novel
Prior art date
Application number
AT97930804T
Other languages
English (en)
Inventor
Yuichi Hirata
Junichi Nezu
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16166915&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE294863(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE294863T1 publication Critical patent/ATE294863T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT97930804T 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren ATE294863T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18521696 1996-07-15
PCT/JP1997/002456 WO1998002543A1 (fr) 1996-07-15 1997-07-15 Nouveaux facteurs analogues au vegf

Publications (1)

Publication Number Publication Date
ATE294863T1 true ATE294863T1 (de) 2005-05-15

Family

ID=16166915

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930804T ATE294863T1 (de) 1996-07-15 1997-07-15 Neuartige vegf-ähnliche faktoren

Country Status (8)

Country Link
US (4) US6828426B1 (de)
EP (1) EP0935001B2 (de)
JP (1) JP3911028B2 (de)
AT (1) ATE294863T1 (de)
AU (1) AU733322B2 (de)
DE (1) DE69733204T3 (de)
ES (1) ES2242227T5 (de)
WO (1) WO1998002543A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
EP1353952B1 (de) 1994-11-14 2007-04-11 Ludwig Institute For Cancer Research Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ATE242809T1 (de) * 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
ATE294863T1 (de) 1996-07-15 2005-05-15 Chugai Pharmaceutical Co Ltd Neuartige vegf-ähnliche faktoren
AU729880C (en) 1996-08-23 2001-11-08 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
US6958147B1 (en) * 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
EP1161451A4 (de) 1999-02-26 2006-05-17 Human Genome Sciences Inc Menschliches alpha-endokin und verfahren zu seiner verwendung
US6764820B2 (en) * 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
WO2001064235A1 (en) * 2000-03-02 2001-09-07 Ludwig Institute For Cancer Research Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor d
US20020102260A1 (en) 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
EP1519193B1 (de) * 2000-03-02 2011-11-09 Vegenics Pty Ltd Verfahren zum Auffinden von Tumoren welche den vaskulären endothelialen Wachstumsfaktor D exprimieren
EP1803730A1 (de) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albuminfusionsproteine
AU2001264565B2 (en) * 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
EP1997829A1 (de) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin Fusionsproteine
CN100418981C (zh) 2002-06-10 2008-09-17 瓦西尼斯公司 在乳腺癌和膀胱癌中差异表达的基因及编码多肽
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
AU2006279462A1 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified VEGF and PDGF with improved angiogenic properties
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US20100029491A1 (en) * 2008-07-11 2010-02-04 Maike Schmidt Methods and compositions for diagnostic use for tumor treatment
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
MX368730B (es) 2013-02-18 2019-10-14 Vegenics Pty Ltd Moleculas que unen ligando y usos de las mismas.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291047B6 (cs) 1992-10-28 2002-12-11 Genentech, Inc. Farmaceutický prostředek obsahující antagonisty faktoru růstu vaskulárních endoteliálních buněk
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
DE69434115T2 (de) 1993-03-25 2005-10-27 Merck & Co., Inc. Inhibitor des wachstumsfaktors für gefässendothelzellen
HU222989B1 (hu) 1993-09-03 2004-01-28 Chugai Seiyaku Kabushiki Kaisha Apoptózist kiváltó monoklonális ellenanyagok
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
ATE294863T1 (de) 1996-07-15 2005-05-15 Chugai Pharmaceutical Co Ltd Neuartige vegf-ähnliche faktoren
AU729880C (en) * 1996-08-23 2001-11-08 Vegenics Limited Recombinant vascular endothelial cell growth factor D (VEGF-D)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor

Also Published As

Publication number Publication date
WO1998002543A1 (fr) 1998-01-22
AU3461097A (en) 1998-02-09
US6828426B1 (en) 2004-12-07
JP3911028B2 (ja) 2007-05-09
US20060172343A1 (en) 2006-08-03
EP0935001B9 (de) 2007-01-24
EP0935001B1 (de) 2005-05-04
EP0935001A4 (de) 2000-08-23
DE69733204D1 (de) 2005-06-09
AU733322B2 (en) 2001-05-10
ES2242227T5 (es) 2011-12-09
US20050112665A1 (en) 2005-05-26
EP0935001A1 (de) 1999-08-11
US7803576B2 (en) 2010-09-28
DE69733204T3 (de) 2012-03-08
ES2242227T3 (es) 2005-11-01
US20110293602A1 (en) 2011-12-01
EP0935001B2 (de) 2011-08-10
DE69733204T2 (de) 2006-05-11

Similar Documents

Publication Publication Date Title
ATE294863T1 (de) Neuartige vegf-ähnliche faktoren
Kreiss et al. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer
JP2004537260A5 (de)
DK288183A (da) Fremgangsmaade til fremstilling af et oligonucleotidt terapeutisk middel
NL990033I1 (nl) Tumornecrosefactor, werkwijzen om het te bereiden,samenstellingen die het bevatten, DNA dat ervoor codeert en proefmethoden met dergelijk DNA.
AU6847298A (en) Transcription factor islet-brain 1 (ib1)
DK0814827T3 (da) Karendotel-vækstfaktor-B
Gao et al. Gene therapy for obesity: progress and prospects
SE8105657L (sv) Mikrobiell framstellning av humanfibroblastinterferon
WO2003023000A3 (en) Linear dna fragments for gene expression
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
WO2003049700A3 (en) Growth hormone releasing hormone suplementation for treating chronically ill subjects
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
WO1998011234A3 (en) Human protein kinases
WO2002050111A3 (en) Isolated laminin 10
HUP0002913A2 (hu) Eljárások és készítmények szekretált fehérjéket, például béta-interferont kódoló géneket alkalmazó terápiára
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
ATE91717T1 (de) Verfahren zur herstellung von proteinen in loeslicher form.
WO2004093920A3 (en) Ghrh for use in treating chronic renal failure
WO2003068954A8 (de) Mikroorganismus zur gentherapeutischen behandlung proliferativer erkrankungen
WO2000005416A3 (en) Fgf-bp promoter sequences as sensors of drug effects
WO1998012220A3 (en) Novel tumor proteins
EP1426444A3 (de) Verwendung des angiogenischen Faktors VEGF145 in der Behandlung kardiovaskulärer Krankheiten
WO1998015635A3 (en) Treatment of cancer using a recombinant poxvirus containing a nucleic acid sequence encoding a cytokine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties